🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/12/2018 | 168,06 | 169,62 | 161,35 | 163,43 | -1,65% | 4,92% | 1.593.200 |
| 17/12/2018 | 169,64 | 171,41 | 164,48 | 166,17 | -2,29% | 4,09% | 1.765.100 |
| 14/12/2018 | 171,38 | 172,00 | 169,63 | 170,06 | -1,94% | 1,38% | 916.900 |
| 13/12/2018 | 175,06 | 177,49 | 171,60 | 173,42 | -1,16% | 3,36% | 971.200 |
| 12/12/2018 | 176,20 | 178,62 | 174,72 | 175,45 | +1,28% | 2,21% | 905.000 |
| 11/12/2018 | 176,29 | 176,56 | 170,86 | 173,23 | -0,32% | 3,23% | 1.023.600 |
| 10/12/2018 | 172,98 | 174,37 | 167,63 | 173,78 | +0,91% | 3,90% | 907.100 |
| 07/12/2018 | 178,03 | 179,55 | 170,90 | 172,21 | -4,12% | 4,86% | 1.627.300 |
| 06/12/2018 | 175,37 | 179,76 | 174,00 | 179,61 | +0,94% | 3,28% | 1.906.300 |
| 04/12/2018 | 184,74 | 187,76 | 177,41 | 177,93 | -3,64% | 5,60% | 1.316.200 |
| 03/12/2018 | 182,60 | 186,79 | 181,92 | 184,65 | +2,14% | 2,67% | 1.692.900 |
| 30/11/2018 | 179,60 | 181,00 | 178,33 | 180,79 | +0,75% | 1,49% | 1.096.000 |
| 29/11/2018 | 176,89 | 181,65 | 176,89 | 179,45 | +0,60% | 2,69% | 976.400 |
| 28/11/2018 | 175,51 | 178,42 | 172,34 | 178,38 | +1,67% | 3,46% | 1.445.100 |
| 27/11/2018 | 168,43 | 176,60 | 168,43 | 175,45 | +4,81% | 4,85% | 2.327.600 |
| 26/11/2018 | 164,30 | 167,70 | 162,89 | 167,40 | +4,37% | 2,93% | 1.604.000 |
| 23/11/2018 | 158,76 | 161,99 | 157,40 | 160,39 | +0,09% | 2,89% | 346.800 |
| 21/11/2018 | 160,57 | 162,48 | 159,06 | 160,25 | +0,31% | 2,13% | 874.200 |
| 20/11/2018 | 161,35 | 161,92 | 157,29 | 159,76 | -0,81% | 2,87% | 1.658.200 |
| 19/11/2018 | 164,76 | 165,57 | 159,77 | 161,07 | -2,45% | 3,52% | 1.362.900 |
| 16/11/2018 | 166,26 | 167,99 | 164,67 | 165,11 | -0,94% | 2,00% | 1.924.100 |
| 15/11/2018 | 163,75 | 167,69 | 162,67 | 166,67 | +1,27% | 3,07% | 1.648.100 |
| 14/11/2018 | 171,98 | 173,32 | 163,13 | 164,58 | -3,36% | 5,93% | 1.502.600 |
| 13/11/2018 | 174,07 | 175,80 | 170,07 | 170,31 | -1,47% | 3,29% | 955.700 |
| 12/11/2018 | 180,55 | 181,45 | 171,70 | 172,85 | -4,26% | 5,40% | 1.754.100 |
| 09/11/2018 | 179,61 | 180,56 | 176,79 | 180,55 | +0,16% | 2,10% | 1.845.500 |
| 08/11/2018 | 183,91 | 185,57 | 179,63 | 180,26 | -1,97% | 3,23% | 1.101.800 |
| 07/11/2018 | 177,34 | 184,14 | 176,56 | 183,88 | +4,94% | 4,27% | 1.536.000 |
| 06/11/2018 | 175,21 | 178,35 | 174,12 | 175,23 | +0,37% | 2,41% | 920.200 |
| 05/11/2018 | 172,08 | 175,15 | 171,70 | 174,59 | +0,75% | 2,00% | 801.400 |